I think IL-10 has a role in SASP feedback
chatGPT(5.6paid):
Overall assessment
This is a narrative review proposing that cellular senescence helps sustain chronic inflammatory skin disease through a bidirectional feedback loop:
[
\text{inflammation} \rightarrow \text{cellular stress/senescence} \rightarrow \text{SASP} \rightarrow \text{more inflammation}
]
Its central idea is biologically plausible and potentially useful. However, the paper repeatedly presents associations and indirect evidence as proof of causation, and its therapeutic section contains important citation mismatches and several claims that appear substantially stronger than the cited evidence permits.
1. Summary of the paper
Liang, Li and Zhang review cellular senescence in three disease settings:
- psoriasis;
- atopic dermatitis;
- systemic lupus erythematosus, including its cutaneous manifestations.
Cellular-senescence framework
The authors describe senescence as a state involving:
- persistent cell-cycle arrest;
- p53–p21 and p16–Rb signalling;
- DNA-damage responses;
- telomere dysfunction;
- mitochondrial abnormalities and oxidative stress;
- SA-β-gal activity;
- a senescence-associated secretory phenotype, or SASP.
Potential triggers include telomere shortening, ROS, chronic inflammatory cytokines, DNA damage and failure of immune clearance.
The SASP includes IL-1, IL-6, TNF-α, chemokines, growth factors and matrix-remodelling enzymes. These factors can recruit immune cells, damage tissue and induce paracrine senescence in neighbouring cells.
Psoriasis
The paper argues that senescent keratinocytes, fibroblasts and some T-cell populations contribute to psoriasis.
Proposed mechanisms include:
- oxidative stress and DNA damage activating p53–p21;
- p16–Rb-mediated cell-cycle arrest;
- IGFBP2 stabilising cytoplasmic p21;
- abnormal RAS–PI3K–AKT signalling;
- altered expression of ID4, CCND1, CXCL1 and IRF7;
- SASP reinforcement of the IL-17/IL-23-dominated inflammatory environment.
The review therefore treats senescence as a possible contributor to chronicity and recurrence, rather than psoriasis being solely a conventional immune-mediated disease.
Atopic dermatitis
For atopic dermatitis, the authors link chronic type-2 inflammation, barrier damage and oxidative stress to keratinocyte and fibroblast senescence.
They highlight Nrf2 as a context- and dose-dependent regulator:
- inadequate Nrf2 activity may leave keratinocytes vulnerable to oxidative injury;
- appropriate Nrf2 activation may reduce DNA damage, inflammation and senescence;
- excessive or prolonged activation might produce different effects.
This is connected to the possibility of topical Nrf2-directed treatment, although the evidence described is predominantly preclinical.
SLE and cutaneous lupus
The paper discusses senescence in:
- mesenchymal stromal/stem cells;
- T cells;
- neutrophils;
- keratinocytes.
Suggested pathways include p16, p53–p21, PI3K–AKT, mTOR and Wnt/β-catenin. SOX4 overexpression and rapamycin treatment of mesenchymal cells are presented as possible means of restoring cell function in experimental SLE systems.
Much of this evidence concerns systemic SLE biology or bone-marrow-derived cells, however, rather than senescence specifically within cutaneous lupus lesions.
Proposed treatments
The paper divides treatment into three broad classes:
-
Senolytics
Agents intended to eliminate senescent cells, including dasatinib plus quercetin, fisetin and BCL-2/BCL-xL inhibitors. -
Senomorphics
Agents intended to suppress the harmful SASP without killing the cells, including mTOR, JAK–STAT, Nrf2 and Wnt/β-catenin modulation. -
Conventional biologics with indirect anti-senescence effects
Anti-IL-17/IL-23 treatment in psoriasis, type-2 cytokine inhibition in atopic dermatitis and BAFF inhibition in SLE are proposed to reduce the inflammatory stimuli that promote senescence.
The authors acknowledge problems with cell specificity, skin delivery, senescent-cell heterogeneity, biomarker reliability, dosing and long-term safety.
2. What is genuinely novel?
This is a review, not an experimental paper, so it does not establish a new biological finding. Its novelty lies primarily in synthesis and framing.
A. Integration across several inflammatory skin diseases
Its strongest contribution is placing psoriasis, atopic dermatitis and lupus into a common senescence–inflammation framework. Reviews exist on skin ageing, inflammaging and individual diseases, but this paper tries to organise them around a single reciprocal mechanism.
B. Senescence as an active disease-maintaining process
The paper moves beyond the proposition that chronic inflammation merely causes premature cellular ageing. It suggests that senescent cells may actively maintain disease by:
- secreting SASP factors;
- inducing paracrine senescence;
- impairing barrier repair;
- altering immune-cell recruitment;
- making inflammation resistant to resolution.
That is a useful conceptual shift, although it remains incompletely demonstrated in patients.
C. Distinction between direct and indirect senescence therapies
The separation into:
- senolytics;
- senomorphics;
- conventional biologics that indirectly reduce senescence-promoting inflammation
is clinically useful. In particular, the third category recognises that established anti-inflammatory drugs might already interrupt the loop without being intrinsically senolytic.
D. Emphasis on topical delivery
The suggestion that topical senolytics or senomorphics could exploit the accessibility of skin while limiting systemic toxicity is potentially important. Skin disease may offer an unusually tractable setting for testing local senescence-directed interventions and obtaining repeated biopsies.
Limits to that novelty
Most individual components—SASP, p16/p21, ROS, mTOR, Nrf2, JAK–STAT and senolytics—are already well established. The paper’s novelty is therefore best described as an integrative hypothesis and translational roadmap, not discovery of a new pathway.
3. Major critique
3.1 It does not demonstrate that senescence is a “driver”
The title calls senescence a “hidden driver,” and the conclusion calls it a “central pathogenic driver.” But most of the evidence reviewed is:
- cross-sectional;
- based on marker expression;
- derived from cultured cells;
- obtained from mouse models;
- or inferred from pathways shared by inflammation and senescence.
These observations establish association more readily than causation.
To demonstrate a driver, one would want evidence that:
- senescent cells appear before or early in disease development;
- their selective removal prevents or reverses disease;
- the benefit is lost when senescent-cell clearance is blocked;
- SASP manipulation alters disease independently of ordinary immunosuppression.
The paper does not systematically grade its evidence against these criteria.
3.2 Senescence is difficult to distinguish from stress, differentiation and inflammation
The authors acknowledge that no single specific marker exists, but the disease sections frequently treat p16, p21, SA-β-gal, ROS or inflammatory cytokines as evidence of senescence.
None is individually decisive:
- p21 can indicate a transient DNA-damage checkpoint;
- p16 can occur outside classical senescence;
- SA-β-gal reflects increased lysosomal content and can be seen in other conditions;
- inflammatory cytokines are not specific to SASP;
- non-proliferating or terminally differentiated keratinocytes are not necessarily senescent;
- dysfunctional or exhausted T cells are not automatically equivalent to senescent somatic cells.
A rigorous definition should combine persistent arrest with several orthogonal markers, cell identity, spatial localisation and ideally functional evidence.
3.3 “Irreversible arrest” is treated too rigidly
The paper repeatedly defines senescence as irreversible cell-cycle arrest. That remains a conventional definition, but contemporary evidence shows that some cells carrying senescence-like markers can escape arrest under certain conditions.
A better formulation would be a stable or persistent stress-associated state, while distinguishing:
- deep senescence;
- transient senescence-like states;
- quiescence;
- exhaustion;
- terminal differentiation;
- reversible inflammatory arrest.
This distinction is especially important in skin, where differentiation and proliferative status vary sharply across epidermal layers.
3.4 The review method is not systematic
Despite saying that it “systematically outlines” the field, the paper provides no:
- search strategy;
- databases;
- search dates;
- inclusion or exclusion criteria;
- study-quality assessment;
- evidence-grading framework.
It is therefore a conventional narrative review. This makes it difficult to know whether contradictory or negative studies were missed.
3.5 Evidence from different tissues is sometimes transferred too freely
Several mechanistic examples come from:
- endothelial cells;
- embryonic fibroblasts;
- lung fibroblasts;
- liver fibrosis;
- cartilage;
- mammary epithelium;
- bone-marrow mesenchymal cells;
- Alzheimer’s disease studies.
These may illustrate general senescence biology, but they do not necessarily establish the same mechanism in keratinocytes or inflammatory skin lesions. The paper frequently moves from “this occurs in another cell system” to “therefore it contributes to this skin disease” without making the inferential step explicit.
3.6 SLE is not handled consistently as a skin disorder
The review includes SLE alongside psoriasis and atopic dermatitis, but much of its SLE evidence concerns systemic immune cells, marrow-derived mesenchymal cells, nephritis and autoantibody production.
It does not clearly separate:
- systemic SLE;
- cutaneous manifestations of systemic SLE;
- acute cutaneous lupus;
- subacute cutaneous lupus;
- chronic/discoid cutaneous lupus.
Consequently, systemic senescence evidence is sometimes used to support claims about cutaneous pathology without direct lesion-specific evidence.
4. Apparent technical and citation problems
These are the most serious weaknesses.
Incorrect description of the p16–Rb mechanism
On page 2, the paper says p16 binding to CDK4/6 prevents the dephosphorylation of Rb.
This appears backwards. p16 inhibits cyclin D–CDK4/6 and thereby prevents Rb phosphorylation. Hypophosphorylated Rb remains active and binds E2F, suppressing S-phase entry.
This is a substantive mechanistic error in a core pathway.
Unsupported claim about clinical D+Q trials in dermatoses
On page 8, the paper claims:
- phase I and II trials of senolytics are underway in chronic inflammatory dermatoses;
- early clinical data show intermittent oral dasatinib plus quercetin reduces dermatological disease-activity scores and circulating senescence markers.
But reference 62 is a 2024 study of skin rejuvenation described as in vitro and in vivo work, not an identifiable phase I/II trial in chronic inflammatory dermatosis. No trial identifiers are supplied.
This makes one of the paper’s central translational claims appear unsupported.
Alzheimer’s trial cited as evidence for skin-disease models
Reference 66 is a phase I feasibility trial of senolytic therapy in mild Alzheimer’s disease. Yet it appears in a paragraph claiming consistent preclinical evidence from mouse models of psoriasis, atopic dermatitis and SLE.
That citation does not support the stated claim.
References 63–64 do not support the full breadth of the claims
Reference 63 concerns topical BCL-2 inhibition in an imiquimod psoriasis model. Reference 64 is a review of flavonoids in photoageing and psoriasis.
Together they do not substantiate the broad claim that senolytics consistently:
- work across psoriasis, AD and SLE models;
- restore barrier proteins;
- reduce T-cell and neutrophil infiltration;
- selectively clear multiple relevant cell types.
Parts may be true, but the cited evidence does not adequately cover the complete statement.
Nrf2 section is internally confusing
The paper says elevated Nrf2 activity may drive pathological senescence and SASP amplification, then immediately advocates pharmacological Nrf2 activation to reduce senescence.
A genuinely dose-dependent or context-dependent model is possible, but the review does not define:
- which level of activation is protective;
- when activation becomes harmful;
- whether effects differ by epidermal layer or cell type;
- whether timing or duration determines the outcome.
Thus “Nrf2 modulation” may be defensible, but a simple Nrf2-agonist therapeutic conclusion is not yet adequately supported.
Overstatement of JAK-inhibitor evidence
The authors state that phase II/III trials provide clinical validation that JAK inhibitors remodel the senescent microenvironment. Yet the cited clinical literature principally evaluates disease severity and inflammatory outcomes, not direct, validated measurements of senescent-cell burden.
Furthermore, the assertion that these agents reduce the “incidence of infections” is questionable as a class-level statement: infection risk is a recognised safety concern with systemic JAK inhibition. Disease control might reduce some disease-associated infections in particular settings, but the paper needs much more precise wording and evidence.
Biologic effects on senescence are largely inferred
The paper claims that dupilumab, psoriasis biologics and belimumab attenuate senescence. But improvements in inflammation or barrier function do not establish that these drugs:
- eliminate senescent cells;
- reverse stable arrest;
- or directly suppress SASP.
The evidence is better interpreted as showing that anti-inflammatory therapy may reduce senescence-inducing stress.
5. Conceptual omissions
Beneficial senescence receives too little attention
Senescence can be beneficial in:
- wound healing;
- tumour suppression;
- limiting damaged-cell proliferation;
- tissue remodelling;
- recruitment of immune clearance.
Removing senescent cells indiscriminately from skin could impair repair or permit damaged cells to persist. The authors mention loss of beneficial cells briefly but do not integrate this into their therapeutic analysis.
The SASP is treated as uniformly inflammatory
SASP composition varies with:
- cell type;
- inducing stimulus;
- duration;
- tissue;
- immune environment;
- senescence stage.
Not all SASPs are identical, and some components facilitate repair or immune clearance. A generic “SASP causes inflammation” model loses this important heterogeneity.
Alternative direction of causality is insufficiently considered
Senescence markers may be consequences of long-standing inflammation rather than independent disease-maintaining mechanisms. Effective anti-inflammatory treatment could reduce these markers because it removes the initiating stress, not because senescence was the primary driver.
A useful design would compare four causal models:
- senescence initiates disease;
- inflammation initiates senescence;
- both are driven by a third process;
- a reciprocal loop develops only after disease is established.
Age-dependent predictions are not adequately tested
Table 1 proposes differences between younger and older patients, such as greater senescent-cell accumulation and more refractory disease in older people. These are plausible but are presented rather categorically and without a clearly synthesised clinical evidence base.
6. What studies would test the hypothesis properly?
The most informative next study would combine:
- Human lesional and non-lesional biopsies, stratified by age and disease activity.
- Cell-type-resolved analysis, distinguishing keratinocytes, fibroblasts, endothelial cells and immune populations.
- Multiple senescence measures, such as p16/p21, proliferation markers, DNA-damage foci, lipofuscin/GL13, lysosomal activity and senescence transcriptomic signatures.
- Spatial transcriptomics or multiplex imaging, showing where senescent cells sit relative to inflammatory infiltrates.
- Longitudinal sampling before and after treatment, to determine whether senescence burden predicts relapse or merely tracks inflammation.
- Selective experimental perturbation, using genetic senescent-cell clearance or locally delivered senolytics.
- Controls for ordinary anti-inflammatory activity, so that improvement can be attributed specifically to senescence targeting.
An especially persuasive clinical trial would compare a topical senolytic against:
- vehicle;
- a conventional topical anti-inflammatory agent;
- and combination treatment.
It should measure both clinical outcomes and direct tissue senescence endpoints.
Bottom line
The paper offers a valuable organising hypothesis: persistent inflammatory skin disease may be reinforced by a senescence–SASP–inflammation feedback loop. Its most useful contribution is to bring multiple dermatoses and therapeutic approaches into this common framework.
But it should be read as a hypothesis-generating narrative review, not evidence that senescence is already established as a central causal driver. The clinical translation section is notably overconfident, and several claims—including those concerning D+Q trials, JAK inhibitors and cross-disease senolytic efficacy—are poorly matched to the cited references. The apparent error in its description of p16–Rb signalling further weakens confidence in the technical precision of the review.